NY Lasik

The NIDEK EC-5000 Excimer Laser System (including EC-5000CX/CXII) has been approved for use in the United States to perform photorefractive keratectomy (PRK) for the reduction or elimination of myopia in the low, moderate or high ranges (-0.75 to -13.00 D), spherical equivalent at the spectacle plane, uncomplicated by refractive astigmatism (i.e. equal or less than 0.75 D in any meridian), and of moderate myopia with astigmatism from -1.00 to -8.00 D spherical equivalent with astigmatism from -0.50 to -4.00 D absolute cylinder by manifest refraction in subjects who are 21 years or older, and to perform laser in-situ keratomileusis (LASIK) for the correction of myopia ranging from -1.00 D to -14.00 D MRSE with or without less than or equal to -4.00 D astigmatism; in patients who are over 21 years of age; and in patients with documentation of stable manifest refraction as defined in the indications statement over the past year.Continue reading “Study of Indication and use of Nidek in treating myopia and astigmatism”

I’ve decided to expand the lasik blog somewhat to include areas beyond New York. Here’s something I found recently…
NIDEK Hyperopia Clinical Study Update & Future FDA Studies

-Fremont, CA USA, May 4th, 2004-

NIDEK, Inc. announced today that it has completed and submitted 3-month clinical data for its new hyperopia study to the FDA. This marks an important milestone in the study process, as additional treatment eyes will be initiated in the study protocol effective immediately. NIDEK also received approval from the FDA to expand the clinical study to 300 eyes under the current treatment protocol. The expansion will include 150 eyes each for spherical hyperopia and hyperopic astigmatism. NIDEK has worked closely with the FDA on the design, initiation and evaluation of the clinical study.
Continue reading “Nidek Seeks Hyperopia Approval from FDA”